Blackstone Is Paying Up to $1.5 Billion for Pfizer’s Answer to Wegovy
Pfizer just convinced Wall Street's biggest private investor to shoulder its obesity bet, yet the payoff for shareholders may not come from the drug at all. The real story sits in who keeps the upside and what arrives first.